Acute myeloid leukemia with normal cytogenetics (Q38027047)

27 August 2017

title

Acute myeloid leukemia with normal cytogenetics (English)

1 reference

27 August 2017

1 reference

acute myeloid leukemia

1 reference

2

Elihu H Estey

1 reference

27 August 2017

Raya Mawad

1

1 reference

27 August 2017

publication date

1 October 2012

1 reference

27 August 2017

published in

Current Oncology Reports

1 reference

27 August 2017

volume

14

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

359-368

1 reference

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

The roles of FLT3 in hematopoiesis and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: ...

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Implications of NRAS mutations in AML: a study of 2502 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CAL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Prognostically useful gene-expression profiles in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Functional proteomic profiling of AML predicts response and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Distinct microRNA expression profiles in acute myeloid leukemia with common translocations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

MicroRNA expression in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0252-X

Molecular characterization of acute myeloid leukemia

21 January 2018

1 reference

12 December 2020

MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis

1 reference

12 December 2020

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

1 reference

12 December 2020

FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia

1 reference

12 December 2020

Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461

1 reference

12 December 2020

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

1 reference

12 December 2020

High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21

1 reference

12 December 2020

The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia

1 reference

12 December 2020

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

1 reference

12 December 2020

1 reference

12 December 2020

Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax

1 reference

12 December 2020

Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML

1 reference

12 December 2020

Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene

1 reference

12 December 2020

High Expression Levels of theETS-Related Gene,ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

1 reference

12 December 2020

Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB

1 reference

12 December 2020

10.1007/S11912-012-0252-X

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1008381338

0 references

1 reference